,address1,city,zip,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,exDividendDate,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationMean,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,Landsteinerstrasse 5,Dreieich,63303,Germany,49 61 03 801 0,49 61 03 801 150,https://www.biotest.com,Biotechnology,Healthcare,"Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and Yimmugo for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.",2307,"{'maxAge': 1, 'name': 'Dr. Michael  Ramroth', 'age': 60, 'title': 'Chairman of the Management Board & CEO', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 2045000, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,31.2,31.6,31.4,31.6,31.2,31.6,31.4,31.6,1651795200,0.0,0.274774,40.256413,3,3,571,87,87,31.2,31.4,53100,20000,1460187904,29.6,35.5,2.7125912,31.456,32.3805,0.0,0.0,EUR,1871218176,-0.018760001,20759018,19785700,0.0,0.02118,9.253,3.393494,1672444800,1703980800,1688083200,-10100000,-0.28,0.78,3:1,1436918400,3.476,51.407,GER,EQUITY,BIO3.DE,BIO3.DE,BIOTEST AG VZ O.N.,Biotest Aktiengesellschaft,911289600,Europe/Berlin,CEST,7200000,31.4,3.0,hold,58300000,1.444,36400000,662099968,2.05,5.055,538300032,177.269,11.213,0.00464,-0.027590001,-124087504,-117200000,0.152,0.26064,0.06762,0.01598,EUR,
1,Landsteinerstrasse 5,Dreieich,63303,Germany,49 61 03 801 0,49 61 03 801 150,https://www.biotest.com,Biotechnology,Healthcare,"Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and Yimmugo for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.",2307,"{'maxAge': 1, 'name': 'Dr. Jorg  Schuttrumpf', 'age': 48, 'title': 'Chief Scientific Officer & Member of the Management Board', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 581000, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,31.2,31.6,31.4,31.6,31.2,31.6,31.4,31.6,1651795200,0.0,0.274774,40.256413,3,3,571,87,87,31.2,31.4,53100,20000,1460187904,29.6,35.5,2.7125912,31.456,32.3805,0.0,0.0,EUR,1871218176,-0.018760001,20759018,19785700,0.0,0.02118,9.253,3.393494,1672444800,1703980800,1688083200,-10100000,-0.28,0.78,3:1,1436918400,3.476,51.407,GER,EQUITY,BIO3.DE,BIO3.DE,BIOTEST AG VZ O.N.,Biotest Aktiengesellschaft,911289600,Europe/Berlin,CEST,7200000,31.4,3.0,hold,58300000,1.444,36400000,662099968,2.05,5.055,538300032,177.269,11.213,0.00464,-0.027590001,-124087504,-117200000,0.152,0.26064,0.06762,0.01598,EUR,
2,Landsteinerstrasse 5,Dreieich,63303,Germany,49 61 03 801 0,49 61 03 801 150,https://www.biotest.com,Biotechnology,Healthcare,"Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and Yimmugo for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.",2307,"{'maxAge': 1, 'name': 'Mr. Peter  Janssen', 'age': 54, 'title': 'COO & Member of Management Board', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 288000, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,31.2,31.6,31.4,31.6,31.2,31.6,31.4,31.6,1651795200,0.0,0.274774,40.256413,3,3,571,87,87,31.2,31.4,53100,20000,1460187904,29.6,35.5,2.7125912,31.456,32.3805,0.0,0.0,EUR,1871218176,-0.018760001,20759018,19785700,0.0,0.02118,9.253,3.393494,1672444800,1703980800,1688083200,-10100000,-0.28,0.78,3:1,1436918400,3.476,51.407,GER,EQUITY,BIO3.DE,BIO3.DE,BIOTEST AG VZ O.N.,Biotest Aktiengesellschaft,911289600,Europe/Berlin,CEST,7200000,31.4,3.0,hold,58300000,1.444,36400000,662099968,2.05,5.055,538300032,177.269,11.213,0.00464,-0.027590001,-124087504,-117200000,0.152,0.26064,0.06762,0.01598,EUR,
3,Landsteinerstrasse 5,Dreieich,63303,Germany,49 61 03 801 0,49 61 03 801 150,https://www.biotest.com,Biotechnology,Healthcare,"Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and Yimmugo for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.",2307,"{'maxAge': 1, 'name': 'Dirk  Schuck', 'age': 44, 'title': 'Member of Supervisory Board', 'yearBorn': 1978, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,31.2,31.6,31.4,31.6,31.2,31.6,31.4,31.6,1651795200,0.0,0.274774,40.256413,3,3,571,87,87,31.2,31.4,53100,20000,1460187904,29.6,35.5,2.7125912,31.456,32.3805,0.0,0.0,EUR,1871218176,-0.018760001,20759018,19785700,0.0,0.02118,9.253,3.393494,1672444800,1703980800,1688083200,-10100000,-0.28,0.78,3:1,1436918400,3.476,51.407,GER,EQUITY,BIO3.DE,BIO3.DE,BIOTEST AG VZ O.N.,Biotest Aktiengesellschaft,911289600,Europe/Berlin,CEST,7200000,31.4,3.0,hold,58300000,1.444,36400000,662099968,2.05,5.055,538300032,177.269,11.213,0.00464,-0.027590001,-124087504,-117200000,0.152,0.26064,0.06762,0.01598,EUR,
4,Landsteinerstrasse 5,Dreieich,63303,Germany,49 61 03 801 0,49 61 03 801 150,https://www.biotest.com,Biotechnology,Healthcare,"Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and Yimmugo for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.",2307,"{'maxAge': 1, 'name': 'Ms. Ainhoa Mendizabal Zubiaga', 'age': 49, 'title': 'Member of Management Board & CFO', 'yearBorn': 1973, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,31.2,31.6,31.4,31.6,31.2,31.6,31.4,31.6,1651795200,0.0,0.274774,40.256413,3,3,571,87,87,31.2,31.4,53100,20000,1460187904,29.6,35.5,2.7125912,31.456,32.3805,0.0,0.0,EUR,1871218176,-0.018760001,20759018,19785700,0.0,0.02118,9.253,3.393494,1672444800,1703980800,1688083200,-10100000,-0.28,0.78,3:1,1436918400,3.476,51.407,GER,EQUITY,BIO3.DE,BIO3.DE,BIOTEST AG VZ O.N.,Biotest Aktiengesellschaft,911289600,Europe/Berlin,CEST,7200000,31.4,3.0,hold,58300000,1.444,36400000,662099968,2.05,5.055,538300032,177.269,11.213,0.00464,-0.027590001,-124087504,-117200000,0.152,0.26064,0.06762,0.01598,EUR,
5,Landsteinerstrasse 5,Dreieich,63303,Germany,49 61 03 801 0,49 61 03 801 150,https://www.biotest.com,Biotechnology,Healthcare,"Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and Yimmugo for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.",2307,"{'maxAge': 1, 'name': 'Dr. Monika  Buttkereit', 'title': 'Head of Investor Relations', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,31.2,31.6,31.4,31.6,31.2,31.6,31.4,31.6,1651795200,0.0,0.274774,40.256413,3,3,571,87,87,31.2,31.4,53100,20000,1460187904,29.6,35.5,2.7125912,31.456,32.3805,0.0,0.0,EUR,1871218176,-0.018760001,20759018,19785700,0.0,0.02118,9.253,3.393494,1672444800,1703980800,1688083200,-10100000,-0.28,0.78,3:1,1436918400,3.476,51.407,GER,EQUITY,BIO3.DE,BIO3.DE,BIOTEST AG VZ O.N.,Biotest Aktiengesellschaft,911289600,Europe/Berlin,CEST,7200000,31.4,3.0,hold,58300000,1.444,36400000,662099968,2.05,5.055,538300032,177.269,11.213,0.00464,-0.027590001,-124087504,-117200000,0.152,0.26064,0.06762,0.01598,EUR,
6,Landsteinerstrasse 5,Dreieich,63303,Germany,49 61 03 801 0,49 61 03 801 150,https://www.biotest.com,Biotechnology,Healthcare,"Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and Yimmugo for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.",2307,"{'maxAge': 1, 'name': 'Dr. Christina  Erb', 'title': 'Head of Corp. HR', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,31.2,31.6,31.4,31.6,31.2,31.6,31.4,31.6,1651795200,0.0,0.274774,40.256413,3,3,571,87,87,31.2,31.4,53100,20000,1460187904,29.6,35.5,2.7125912,31.456,32.3805,0.0,0.0,EUR,1871218176,-0.018760001,20759018,19785700,0.0,0.02118,9.253,3.393494,1672444800,1703980800,1688083200,-10100000,-0.28,0.78,3:1,1436918400,3.476,51.407,GER,EQUITY,BIO3.DE,BIO3.DE,BIOTEST AG VZ O.N.,Biotest Aktiengesellschaft,911289600,Europe/Berlin,CEST,7200000,31.4,3.0,hold,58300000,1.444,36400000,662099968,2.05,5.055,538300032,177.269,11.213,0.00464,-0.027590001,-124087504,-117200000,0.152,0.26064,0.06762,0.01598,EUR,
